

From: David Myers </O=ONETEAM/OU=FIRST ADMINISTRATIVE GROUP/CN=RECIPIENTS /CN=DMYERS>
To: Cristina Garcia
Sent: 7/22/2011 6:17:13 PM
Subject: RE: A347 Oxymorphone Training Materials
Attachments: Oxymorphone Sales Training v2 A347.pptx



Here you go!

Thanks!

D.

David Myers
Senior Manager, Products & Communications



Actavis
60 Columbia Rd. Bldg B t +1 973-993-4503 @ DMYERS@actavis.com
Morristown , NJ 07960 United States f 973-993-4302 w www.actavis.com
Internal VoIP number t 1254503

Please note that this e-mail and its attachments are intended for the named addressee only and may contain information that is confidential and privileged. If you have by coincidence or mistake or without specific authorization received this e-mail and its attachments we request that you notify us immediately that you have received them in error, uphold strict confidentiality and neither read, copy, nor otherwise make use of their content in any way Please note that the sender of this e-mail and its attachments is solely responsible for its content if it does not concern the operations of Actavis Group or its subsidiaries.

From: Cristina Garcia
Sent: Friday, July 22, 2011 2:16 PM
To: David Myers
Subject: FW: A347 Oxymorphone Training Materials

David,


Can u send me the final piece for my files? I can release it once received.

Thanks,

Cristina Garcia
Regulatory Affairs Labeling Associate III



Actavis
200 Elmora Avenue t +1 908-659-2323 @ CGarcia@actavis.com
Elizabeth , NJ 07202 United States w www.actavis.com
Internal VoIP number t 1202323



Highly Confidential



Acquired_Actavis_02230857

P-22000 _ 0001

Please note that this e-mail and its attachments are intended for the named addressee only and may contain information that is confidential and privileged. If you have by coincidence or mistake or without specific authorization received this e-mail and its attachments we request that you notify us immediately that you have received them in error, uphold strict confidentiality and neither read, copy, nor otherwise make use of their content in any way Please note that the sender of this e-mail and its attachments is solely responsible for its content if it does not concern the operations of Actavis Group or its subsidiaries.

From: Arnetha Wharton
Sent: Friday, July 22, 2011 2:02 PM
To: David Myers
Cc: 'Jennifer Altier'; Beth Zelnick-Kaufman; Cristina Garcia; Terri Nataline; Jinping McCormick; Joann Stavole
Subject: RE: A347 Oxymorphone Training Materials

David,

Redaction - Privilege

Thanks,
Arnetha

Arnetha Wharton
Commercial Paralegal



Actavis
60 Columbia Rd. Bldg B t +1 973-889-6973 @ AWharton@Actavis.com
Morristown , NJ 07960 United States w www.actavis.com
Internal VoIP number t 125-6973

Please note that this e-mail and its attachments are intended for the named addressee only and may contain information that is confidential and privileged. If you have by coincidence or mistake or without specific authorization received this e-mail and its attachments we request that you notify us immediately that you have received them in error, uphold strict confidentiality and neither read, copy, nor otherwise make use of their content in any way Please note that the sender of this e-mail and its attachments is solely responsible for its content if it does not concern the operations of Actavis Group or its subsidiaries.

From: David Myers
Sent: Thursday, July 21, 2011 2:25 PM
To: Arnetha Wharton
Cc: 'Jennifer Altier'; Beth Zelnick-Kaufman; Cristina Garcia; Terri Nataline; Jinping McCormick; Joann Stavole
Subject: RE: A347 Oxymorphone Training Materials

Arnetha,

Redaction - Privilege

Rgs,

David

David Myers
Senior Manager, Products & Communications



Actavis

60 Columbia Rd. Bldg B t +1 973-993-4503 @ DMYERS@actavis.com
Morristown , NJ 07960 United States f 973-993-4302 w www.actavis.com
Internal VoIP number t 1254503

Please note that this e-mail and its attachments are intended for the named addressee only and may contain information that is confidential and privileged. If you have by coincidence or mistake or without specific authorization received this e-mail and its attachments we request that you notify us immediately that you have received them in error, uphold strict confidentiality and neither read, copy, nor otherwise make use of their content in any way Please note that the sender of this e-mail and its attachments is solely responsible for its content if it does not concern the operations of Actavis Group or its subsidiaries.

From: Arnetha Wharton
Sent: Thursday, July 21, 2011 1:29 PM
To: David Myers
Cc: 'Jennifer Altier'; Beth Zelnick-Kaufman; Cristina Garcia; Terri Nataline; Jinping McCormick; Joann Stavole
Subject: RE: A347 Oxymorphone Training Materials

David,

Redaction - Privilege

Thanks,
Arnetha

Arnetha Wharton
Commercial Paralegal



Actavis
60 Columbia Rd. Bldg B t +1 973-889-6973 @ AWharton@Actavis.com
Morristown , NJ 07960 United States w www.actavis.com
Internal VoIP number t 125-6973

Please note that this e-mail and its attachments are intended for the named addressee only and may contain information that is confidential and privileged. If you have by coincidence or mistake or without specific authorization received this e-mail and its attachments we request that you notify us immediately that you have received them in error, uphold strict confidentiality and neither read, copy, nor otherwise make use of their content in any way Please note that the sender of this e-mail and its attachments is solely responsible for its content if it does not concern the operations of Actavis Group or its subsidiaries.

From: David Myers
Sent: Wednesday, July 20, 2011 4:48 PM
To: Joann Stavole
Cc: 'Jennifer Altier'; Beth Zelnick-Kaufman; Arnetha Wharton; Cristina Garcia; Terri Nataline; Jinping McCormick
Subject: RE: A347 Oxymorphone Training Materials

Team,

Redaction - Privilege

Best regards,

David

David Myers

Senior Manager, Products & Communications



Actavis

60 Columbia Rd. Bldg B t +1 973-993-4503 @ DMYERS@actavis.com

Morristown , NJ 07960 United States f 973-993-4302 w www.actavis.com

Internal VoIP number t 1254503

Please note that this e-mail and its attachments are intended for the named addressee only and may contain information that is confidential and privileged. If you have by coincidence or mistake or without specific authorization received this e-mail and its attachments we request that you notify us immediately that you have received them in error, uphold strict confidentiality and neither read, copy, nor otherwise make use of their content in any way Please note that the sender of this e-mail and its attachments is solely responsible for its content if it does not concern the operations of Actavis Group or its subsidiaries.

From: Joann Stavole
Sent: Wednesday, July 20, 2011 4:16 PM
To: David Myers
Cc: 'Jennifer Altier'; Beth Zelnick-Kaufman; Arnetha Wharton; Cristina Garcia; Terri Nataline
Subject: RE: A347 Oxymorphone Training Materials

Hi David,

Redaction - Privilege

Thanks

Joann Stavole
Director, Regulatory Affairs, 3rd Party



Actavis

60 Columbia Rd. Bldg B t +1 973-889-6623 @ JSTAVOLE@actavis.com

Morristown , NJ 07960 United States w www.actavis.com

Internal VoIP number t 125-6623

Please note that this e-mail and its attachments are intended for the named addressee only and may contain information that is confidential and privileged. If you have by coincidence or mistake or without specific authorization received this e-mail and its attachments we request that you notify us immediately that you have received them in error, uphold strict confidentiality and neither read, copy, nor otherwise make use of their content in any way Please note that the sender of this e-mail and its attachments is solely responsible for its content if it does not concern the operations of Actavis Group or its subsidiaries.

From: Beth Zelnick-Kaufman

Highly Confidential

Acquired_Actavis_02230860

P-22000 _ 0004

Sent: Wednesday, July 20, 2011 8:42 AM
To: David Myers; Joann Stavole
Cc: Nathalie Leitch; Cristina Garcia
Subject: RE: A347 Oxymorphone Training Materials

David:

Redaction - Privilege

Kind regards,

Beth

Beth Zelnick-Kaufman
Director, Legal



Actavis
60 Columbia Rd. Bldg B t +1 973-889-6684 @ BZelnick-Kaufman@actavis.com
Morristown , NJ 07960 United States f 973-993-4306 w www.actavis.com
Internal VoIP number t 125-6684

Please note that this e-mail and its attachments are intended for the named addressee only and may contain information that is confidential and privileged. If you have by coincidence or mistake or without specific authorization received this e-mail and its attachments we request that you notify us immediately that you have received them in error, uphold strict confidentiality and neither read, copy, nor otherwise make use of their content in any way Please note that the sender of this e-mail and its attachments is solely responsible for its content if it does not concern the operations of Actavis Group or its subsidiaries.

From: David Myers
Sent: Tuesday, July 19, 2011 2:43 PM
To: Joann Stavole
Cc: Nathalie Leitch; Cristina Garcia; Beth Zelnick-Kaufman
Subject: FW: A347 Oxymorphone Training Materials
Importance: High

Hi Joann,

Redaction - Privilege

Thanks,

David

David Myers
Senior Manager, Products & Communications



Actavis
60 Columbia Rd. Bldg B t +1 973-993-4503 @ DMYERS@actavis.com
Morristown , NJ 07960 United States f 973-993-4302 w www.actavis.com
Internal VoIP number t 1254503

Please note that this e-mail and its attachments are intended for the named addressee only and may contain information that is confidential and privileged. If you have by coincidence or mistake or without specific authorization received this e-mail and its attachments we request that you notify us immediately that you have received them in error, uphold strict confidentiality and neither read, copy, nor otherwise make use of their content in any way Please note that the sender of this e-mail and its attachments is solely responsible for its content if it does not concern the operations of Actavis Group or its subsidiaries.

From: David Myers
Sent: Tuesday, July 19, 2011 2:37 PM
To: Cristina Garcia; Beth Zelnick-Kaufman; Arnetha Wharton
Cc: Terri Nataline; Charlene Salmorin; Jinping McCormick
Subject: A347 Oxymorphone Training Materials
Importance: High

Cristina & Beth,

Redaction - Privilege

Thanks for your assistance!

David

David Myers

Senior Manager, Products & Communications



Actavis

60 Columbia Rd. Bldg B t +1 973-993-4503 @ DMYERS@actavis.com

Morristown , NJ 07960 United States f 973-993-4302 w www.actavis.com

Internal VoIP number t 1254503

Please note that this e-mail and its attachments are intended for the named addressee only and may contain information that is confidential and privileged. If you have by coincidence or mistake or without specific authorization received this e-mail and its attachments we request that you notify us immediately that you have received them in error, uphold strict confidentiality and neither read, copy, nor otherwise make use of their content in any way Please note that the sender of this e-mail and its attachments is solely responsible for its content if it does not concern the operations of Actavis Group or its subsidiaries.

File Provided Natively

Introduction of Oxymorphone Hydrochloride Extended-Release Tablets, CII

Sales Training Class





The Latest News from Actavis

Actavis launches generic Oxymorphone Hydrochloride Extended-Release Tablets, CII 7.5mg and 15mg (AB-rated to Opana ER^{®*}) in July

...and we'd like your help to increase awareness regarding the availability of this new product!



Confidential - for internal & training purpose only. Not to be distributed

Oxymorphone Overview

- Oxymorphone Hydrochloride Extended-Release Tablets, CII is available from Actavis in 7.5mg and 15mg, bottles of 100's.
- AB-rated to Opana ER[®]* by Endo Labs.
- Opana ER was originally available in 7 strengths: 5mg, 7.5mg, 10mg, 15mg, 20mg, 30mg and 40mg.
- Endo discontinued the 7.5mg and 15mg strengths in March, 2011. *Normally, it is not necessary to promote a generic product to physicians, but since the brand discontinued these strengths, we have to increase awareness of their availability at the prescribing level. (Endo did not withdraw these strengths due to safety reasons.)*
- We believe that Actavis is the first, and perhaps only, generic available in the 7.5mg and 15mg strengths at initial launch.
- Product launched on July 15th, shipped to all major wholesalers.

© 2011 Actavis Inc.

Confidential - for internal & training
purpose only. Not to be distributed



Key Messages

Example script to use when introducing Actavis' generic Oxymorphone:

- “Doctor, you may know that two strengths of Opana ER^{®*} , 7.5mg and 15mg, were withdrawn earlier this year by Endo. This action was a business decision and these strengths were not withdrawn due to safety reasons. I would like to make you aware that generic versions of these strengths, which are AB-rated to the brand, are now available from Actavis. Please consider prescribing these generic strengths for the appropriate patients.”
- Generic product is stocked at all major wholesalers and readily available.



Sell Sheet - front & back



Generic is now available.

Oxymorphone Hydrochloride Extended-Release Tablets, CII

Actavis is proud to launch Oxymorphone Hydrochloride Extended-Release Tablets, CII 7.5 mg and 15 mg strengths, immediately available. It is AB rated to Opana® ER Oxymorphone hydrochloride Extended-Release tablets and is indicated for the relief of moderate to severe pain in patients requiring continuous around-the-clock opioid treatment for an extended period of time. At Actavis, we are working to meet the demand for high quality lower-cost alternatives to brand name pharmaceuticals.

Please see the following boxed Warning and attached for full prescribing information.

IMPORTANT SAFETY INFORMATION
 Oxymorphone hydrochloride extended-release tablets contain oxymorphone, an opioid agonist and a Schedule II controlled substance, with an abuse liability similar to other opioid analgesics. Oxymorphone can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing oxymorphone hydrochloride extended-release tablets in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse, or diversion. Oxymorphone hydrochloride extended-release tablets are an opioid agonist indicated for the relief of moderate to severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time. Oxymorphone hydrochloride extended-release tablets are NOT intended for use as an as needed analgesic. Oxymorphone hydrochloride extended-release tablets are to be swallowed whole and are not to be broken, chewed, dissolved, or crushed as this leads to rapid release and absorption of a potentially fatal dose of oxymorphone. Patients must not consume alcoholic beverages, prescription or non-prescription medications containing alcohol. Co-ingestion of alcohol with oxymorphone hydrochloride extended-release tablets may result in a potentially fatal overdose of oxymorphone.

Leading the way... with quality generics.

To learn more, call Actavis customer service at 888.925.2342, or visit www.actavis.com.

Now available from Actavis

Oxymorphone Hydrochloride Extended-Release Tablets, CII

- Generic is available in 7.5mg and 15mg strengths
- AB Rated, to Opana ER™
- 100-count bottles
- Another addition to our expanding product portfolio

Product	Strength	Size	NDC#
Oxymorphone Hydrochloride Extended-Release Tablets, CII	7.5 mg	100	0228-3261-11
Oxymorphone Hydrochloride Extended-Release Tablets, CII	15 mg	100	0228-3262-11

To learn more, contact your Actavis representative or wholesaler, or call customer service at 888.925.2342.

Please see attached for full prescribing information.

Confidential - for internal & training purpose only. Not to be distributed

Marketing Support

- A two wave **direct-mail campaign** to the top 10,000 prescribing doctors. The first wave is planned to coincide with our launch to bring awareness to prescribing doctors. A follow-up mailing is planned for four weeks post-launch.
- **Journal advertising** to cover both prescribers and pharmacists:
 - Practical Pain Management - focused on pain specialists. Circulation: 45,000. Insertion in August 2011 issue.
 - Pharmacy Times - focused on Pharmacists/Pharmacy buyers. Circulation: 163,500. Insertion in August 2011 issue.
- **Email campaign** reaching a pharmacy audience of 87,000 addresses.
- Engaging major chains and wholesalers with targeted marketing programs aiming at pharmacist, doctors and patients

Indications and Usage

- Oxymorphone hydrochloride extended-release tablets are indicated for the relief of moderate to severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time.

Limitations of Usage

- Oxymorphone hydrochloride extended-release tablets are not intended for use as an as needed analgesic.
- Oxymorphone hydrochloride extended-release tablets are not indicated for pain in the immediate post-operative period if the pain is mild, or not expected to persist for an extended period of time.
- Oxymorphone hydrochloride extended-release tablets are only indicated for post-operative use if the patient is already receiving the drug prior to surgery or if the post-operative pain is expected to be moderate or severe and persist for an extended period of time. Physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate. (See American Pain Society guidelines).

Oxymorphone Boxed Warning

WARNING: POTENTIAL FOR ABUSE, IMPORTANCE OF PROPER PATIENT SELECTION AND LIMITATIONS OF USE

Potential for Abuse

Oxymorphone hydrochloride extended-release tablets contain oxymorphone, which is a morphine-like opioid agonist and a Schedule II controlled substance, with an abuse liability similar to other opioid analgesics.

Oxymorphone can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing oxymorphone hydrochloride extended-release tablets in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse, or diversion.

Proper Patient Selection

Oxymorphone hydrochloride extended-release tablets are an extended-release oral formulation of oxymorphone indicated for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.

Limitations of Use

Oxymorphone hydrochloride extended-release tablets are NOT intended for use as an as needed analgesic.

Oxymorphone hydrochloride extended-release tablets are to be swallowed whole and are not to be broken, chewed, dissolved, or crushed. Taking broken, chewed, dissolved, or crushed oxymorphone hydrochloride extended-release tablets leads to rapid release and absorption of a potentially fatal dose of oxymorphone.

Patients must not consume alcoholic beverages, or prescription or non-prescription medications containing alcohol, while on oxymorphone hydrochloride extended-release tablet therapy. The co-ingestion of alcohol with oxymorphone hydrochloride extended-release tablets may result in increased plasma levels and a potentially fatal overdose of oxymorphone.

Important Safety Information

IMPORTANT SAFETY INFORMATION

Oxymorphone hydrochloride extended-release tablets contain oxymorphone, an opioid agonist and a Schedule II controlled substance, with an abuse liability similar to other opioid analgesics. Oxymorphone can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing oxymorphone hydrochloride extended-release tablets in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse, or diversion.

Oxymorphone hydrochloride extended-release tablets are an opioid agonist indicated for the relief of moderate to severe pain in patients requiring continuous around-the-clock opioid treatment for an extended period of time. Oxymorphone hydrochloride extended-release tablets are NOT intended for use as an as needed analgesic.

Oxymorphone hydrochloride extended-release tablets are to be swallowed whole and are not to be broken, chewed, dissolved, or crushed as this leads to rapid release and absorption of a potentially fatal dose of oxymorphone. Patients must not consume alcoholic beverages, prescription or non prescription medications containing alcohol. Co-ingestion of alcohol with oxymorphone hydrochloride extended-release tablets may result in a potentially fatal overdose of oxymorphone.

Contraindications

- Oxymorphone hydrochloride extended-release tablets are contraindicated in patients with known hypersensitivity to oxymorphone or any of the tablet components, or with known hypersensitivity to morphine analogs such as codeine. This includes in patients with respiratory depression, and in patients with acute or severe bronchial asthma or hypercarbia.
- Oxymorphone hydrochloride extended-release tablets are contraindicated in any patient who has or is suspected of having paralytic ileus.
- Oxymorphone hydrochloride extended-release tablets are also contraindicated in patients who have moderate or severe hepatic impairment.
- The most serious adverse reactions associated with the use of oxymorphone hydrochloride extended-release tablets are respiratory depression, misuse and abuse, and CNS depressant effects.
- The most common adverse reactions are nausea, constipation, dizziness, somnolence, vomiting, pruritus, headache, sweating increased, and sedation.
- Please visit www.actavis.us/oxymorphone for Full Prescribing Information and other important Safety Information.

FAQs

- Q1: Is the generic product as effective as the brand?
A1: This product is approved by FDA and AB rated to Opana ER^{®*}.
- Q2: What does an AB rating mean?
A2: AB rating means that FDA has determined that the generic product is pharmaceutically and therapeutically equivalent to the brand Opana ER^{®*}.
- Q3: What about the other strengths?
A3: Based on public information, the other strengths may become available in CY 2013.

FAQs - cont'd

- Q4: Where will this product be stocked? Can patients easily get their scripts filled?

A4: This product is stocked at all major wholesalers and major drug chain stores. Patients should be able to get their scripts filled easily.

- Q5: Do I have to do anything special when writing a script?

A5: Nothing different from what you normally do.

- Q6: Are you shifting your focus to marketing generics?

A6: No, KADIAN® is still our focus product; we just want to make you aware that Actavis has a generic division that is marketing this product.

DOs

- Do discuss the generic product availability
- Do mention that generic product is AB rated to Opana ER®*
- Do mention that brand discontinued the 7.5mg and 15mg strengths
- Do mention that Endo did not withdraw these strengths for safety reasons
- Do leave the sell sheet with the prescribers (insert is attached)
- Do mention that this drug contains a boxed warning, so please refer to the complete safety information (as provided in the insert) when considering this drug for your patients

DON'Ts

- Do not provide information outside of the scope of this training
- Do not compare products
- Do not discuss or mention pricing
- We have provided product indication and safety information in this presentation for your information should questions arise. Always remember this is a boxed warning product and any discussion of the indication or benefits must include safety information. *In your interactions with physicians limit conversations regarding the indication of the product or defer to medical affairs as this is not intended to be a risk/benefit discussion. This is merely an availability announcement.*

© 2011 Actavis Inc.

Confidential - for internal & training
purpose only. Not to be distributed



Additional information

- For general medical questions and product information, please contact Medical Affairs:

Call: 800-432-8534, Prompt #2

Fax: 908-659-2685

Email: medicalaffairs@actavis.com

- This is a different number from that used for Kadian



Compensation and Incentives

- **Team Award**
 - Top regional team with the highest cumulative Rx written for the period of August - October 2011
 - Each member of the team wins \$500
- **Individual Award**
 - Top two performers from each team with the highest cumulative Rx written for the period of August - October 2011
 - Each individual award is \$1000
- **Renewable upon review of overall performance**

Prescription Data

Average Monthly TRx				
Strength	Jan-Mar 2011 Average TRx	Apr 2011 TRx	May 2011 TRx	Jun 2011 TRx
15mg	5760	4188	2515	1595
7.5mg	1340	793	511	320
Total TRx	7100	4981	3026	1915

© 2011 Actavis Inc.

Confidential - for internal & training
purpose only. Not to be distributed





Additional Information

- Thank you for your assistance in promoting awareness of this newly-launched Actavis generic product! However, we'd like to confirm that informing prescribers of the availability of generic strengths of Oxymorphone should not detract from your time detailing KADIAN[®]. KADIAN[®] is still the primary focus of your sales call.

KADIAN[®] is a registered trademark of Actavis Elizabeth LLC. All other trademarks are owned by their respective owners.

Thank you!

